Anticalins in Drug Development.
- Published in:
- BioDrugs, 2005, v. 19, n. 5, p. 279, doi. 10.2165/00063030-200519050-00001
- By:
- Publication type:
- Article
Works matching IS 11738804 AND DT 2005 AND VI 19 AND IP 5
Results: 6
1
2
Toward Personalized Immunotherapy for Non-Hodgkin Lymphoma: Targeting the Idiotypic Immunoglobulin.
- Published in:
- BioDrugs, 2005, v. 19, n. 5, p. 289, doi. 10.2165/00063030-200519050-00002
- By:
- Publication type:
- Article
3
The Role of Radioimmunotherapy with Yttrium-90 Ibritumomab Tiuxetan in the Treatment of Non-Hodgkin Lymphoma.
- Published in:
- BioDrugs, 2005, v. 19, n. 5, p. 309, doi. 10.2165/00063030-200519050-00004
- By:
- Publication type:
- Article
4
Spotlight on Subcutaneous Recombinant Interferon-β-1a (Rebif<sup>®</sup>) in Relapsing-Remitting Multiple Sclerosis.
- Published in:
- BioDrugs, 2005, v. 19, n. 5, p. 323, doi. 10.2165/00063030-200519050-00005
- By:
- Publication type:
- Article
5
Darbepoetin Alfa: Its Use in Anemia Associated with Chronic Kidney Disease.
- Published in:
- BioDrugs, 2005, v. 19, n. 5, p. 327, doi. 10.2165/00063030-200519050-00006
- By:
- Publication type:
- Article
6
Mechanisms of Action for Treatments in Multiple Sclerosis: Does a Heterogeneous Disease Demand a Multi-Targeted Therapeutic Approach?
- Published in:
- BioDrugs, 2005, v. 19, n. 5, p. 299, doi. 10.2165/00063030-200519050-00003
- By:
- Publication type:
- Article